

25 February 2025

ASX Announcement

Webcast Recording for the 1H FY25 Results Presentation

For shareholders and other interested parties who were unable to view the 1H FY25 results presentation live, or would like the opportunity to view it again, the recording can be viewed at the link below.

<https://vimeo.com/1059913772>

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

About PolyNovo®

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 67,000+ patients across 46 countries, the company is investing for growth via new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.